| Literature DB >> 30480258 |
Lucy C Beishon1, Ronney B Panerai1,2, Thompson G Robinson1,2, Hari Subramaniam1,3, Victoria J Haunton1,2.
Abstract
BACKGROUND: The incidence of dementia is predicted to rise rapidly, but sensitive diagnostic tests remain elusive. Changes in cerebral blood flow velocity (CBFv) can occur at an early stage of cognitive decline, and can be measured by transcranial Doppler ultrasonography (TCD).Entities:
Keywords: Alzheimer’s disease; cerebral blood flow; dementia imaging; mild cognitive impairment
Year: 2018 PMID: 30480258 PMCID: PMC6218154 DOI: 10.3233/ADR-180068
Source DB: PubMed Journal: J Alzheimers Dis Rep ISSN: 2542-4823
Baseline demographics of participants enrolled in the study. Data are number (percentage) for nominal data, and mean (standard deviation) or median [inter-quartile range] for continuous data. Significance testing by chi-square, one-way analysis of variance or Kruskall-Wallis
| Demographic | n | ALL | Healthy Controls | Mild cognitive impairment | Alzheimer’s disease | |
| n | 30 | 10 | 10 | 10 | ||
| Female sex (n, %) | 30 | 6 (20) | 2 (20) | 2 (20) | 2 (20) | 1.00 |
| Age (y) | 30 | 73.2 (7.0) | 71.4 (5.7) | 73.3 (6.4) | 74.9 (8.7) | 0.55 |
| Caucasian (n, %) | 30 | 29 (96.7) | 10 (100) | 10 (100) | 9 (90) | 0.36 |
| Left Handedness (n, %) | 30 | 5 (16.7) | 1 (10) | 3 (30) | 1 (10) | 0.38 |
| Age at completion of education (y) | 16 [3.8] | 18 [5.5] | 15 [3] | 16 [4.3] | 0.15 | |
| Body mass index | 29 | 25.2 (4.2) | 25.8 (3.2) | 25.4 (5.8) | 24.2 (3.1) | 0.70 |
| Smoker | ||||||
| Current (n, %) | 30 | 2 (6.7) | 0 (0) | 2 (20) | 0 (0) | 0.17 |
| Ex (n, %) | 15 (50) | 4 (40) | 6 (60) | 5 (50) | ||
| Alcohol intake > 14 units/week (n, %) | 30 | 5 (16.7) | 2 (20) | 2 (20) | 1 (10) | 0.79 |
| Diabetes (n, %) | 30 | 1 (3.3) | 0 (0) | 1 (10) | 0 (0) | 0.36 |
| Hypertension (n, %) | 30 | 9 (30) | 2 (20) | 6 (60) | 1 (10) | |
| Hypercholesterolemia (n, %) | 30 | 11 (36.7) | 2 (20) | 6 (60) | 3 (30) | 0.16 |
| Cardiovascular disease (n, %) | 30 | 2 (6.7) | 0 (0) | 1 (10) | 1 (10) | 0.59 |
| Previous stroke (n, %) | 30 | 3 (10) | 0 (0) | 2 (20) | 1 (10) | 0.33 |
| Depression (n, %) | 30 | 2 (6.7) | 0 (0) | 1 (10) | 1 (10) | 0.59 |
| Antidepressant use (n, %) | 30 | 3 (10) | 0 (0) | 2 (20) | 1 (10) | 0.33 |
| Acetylcholinesterase inhibitor use (n, %) | 30 | 12 (40) | 0 (0) | 3 (30) | 9 (90) | |
| Antihypertensive use (n, %) | 30 | 8 (26.7) | 1 (10) | 5 (50) | 2 (20) | 0.11 |
| ACE-III total score | 30 | 87 [17] | 96.5 [3.0] | 87 [7.3] | 77.5 [9.5] | |
| ACE-III Language score | 30 | 4 [0] | 4 [0] | 4 [0] | 4 [0] | 0.38 |
Baseline parameters for healthy control, Alzheimer’s disease, and mild cognitive impairment groups. CBFv, cerebral blood flow velocity; MAP, mean arterial pressure; ETCO2, end-tidal CO2. Data are presented as mean (standard deviation). Significance testing by one-way ANOVA
| Parameter | Healthy controls | Alzheimer’s disease | Mild cognitive impairment | |
| n | 10 | 10 | 10 | |
| CBFv non-dominant (cm/s) | 44.4 (9.4) | 42.7 (7.3) | 46.2 (7.8) | 0.64 |
| CBFv dominant (cm/s) | 45.7 (7.1) | 42.8 (8.0) | 45.0 (8.1) | 0.69 |
| MAP (mmHg) | 98.2 (15.0) | 85.2 (29.7) | 91.7 (13.6) | 0.39 |
| Heart rate (bpm) | 64.8 (12.7) | 64.3 (13.5) | 66.6 (7.2) | 0.90 |
| ETCO2 (mmHg) | 37.8 (2.7) | 35.9 (2.8) | 37.8 (2.9) | 0.24 |
Parameters at T2 and T3. Data shown are peak percentage change in cerebral blood flow velocity (CBFv), mean arterial pressure (MAP), heart rate and end-tidal CO2 (ETCO2) from a 20-s baseline, in healthy control, mild cognitive impairment, and Alzheimer’s dementia groups. Statistical testing by one-way ANOVA with post-hoc testing by Tukey
| Parameter | n | Healthy controls | Alzheimer’s disease | Mild cognitive impairment | |
| n | |||||
| CBFv Non-dominant | |||||
| T2 | 30 | ||||
| T3 | 30 | 9.4 (8.8) | 1.9 (8.3) | 9.4 (7.3) | 0.08 |
| CBFv Dominant | |||||
| T2 | 30 | ||||
| T3 | 30 | 9.4 (10.0) | –1.5 (5.8) | 9.0 (9.2) | |
| Heart rate | |||||
| T2 | 30 | ||||
| T3 | 30 | 7.3 (5.8) | 2.1 (7.2) | 1.6 (4.8) | 0.08 |
| MAP | |||||
| T2 | 30 | ||||
| T3 | 30 | 6.1 (4.0) | 2.3 (5.1) | 3.7 (4.0) | 0.16 |
| ETCO2 | |||||
| T2 | 30 | ||||
| T3 | 30 | –3.0 (7.8) | –5.5 (6.5) | –1.9 (2.5) | 0.39 |
Fig.1The temporal changes in MAP (a), heart rate (b), and ETCO2 (c), to the language task. All signals were normalized by baseline values. Continuous line = healthy control, dotted line = mild cognitive impairment, interrupted line = Alzheimer’s disease. a) non-dominant hemisphere; b) dominant hemisphere. Task initiation occurred at 20 s.
Fig.2The temporal changes in cerebral blood flow velocity (normalized % CBFv) to the language task. All signals were normalized by baseline values. Continuous line = healthy control, dotted line = mild cognitive impairment. interrupted line = Alzheimer’s disease. a) non-dominant hemisphere; b) dominant hemisphere. Task initiation occurred at 20 s.
Correlation between cognitive test score and peak percentage change in cerebral blood flow velocity (CBFv), for all participants (healthy control, mild cognitive impairment, and Alzheimer’s dementia groups combined). Statistical testing by Spearman correlation, with Bonferroni correction for repeated measures
| Parameter | n | Correlation coefficient | Parameter | n | Correlation coefficient | ||
| Total ACE- III score | Total ACE- III score | ||||||
| CBFv Non-dominant T2 | CBFv Non-dominant T3 | 30 | 0.27 | 0.30 | |||
| CBFv Dominant T2 | 30 | 0.40 | 0.06 | CBFv Dominant T3 | 30 | 0.32 | 0.16 |
| ACE-II Language score | ACE-III Language score | ||||||
| CBFv Non-dominant T2 | 30 | 0.22 | 0.48 | CBFv Non-dominant T3 | 30 | 0.10 | 1.0 |
| CBFv Dominant T2 | 30 | 0.32 | 0.18 | CBFv Dominant T3 | 30 | 0.07 | 1.0 |
Fig.3Positive correlations between normalized percentage change in cerebral blood flow velocity (CBFv) and Addenbrooke’s Cognitive Examination III (ACE-III) score, a = non-dominant hemisphere, b = dominant hemisphere. Correlations by Spearman testing.